Connor Clark & Lunn Investment Management Ltd. Acquires 22,188 Shares of Altimmune, Inc. (NASDAQ:ALT)

Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Altimmune, Inc. (NASDAQ:ALT) by 119.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,705 shares of the company’s stock after purchasing an additional 22,188 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.06% of Altimmune worth $250,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. CANADA LIFE ASSURANCE Co acquired a new stake in shares of Altimmune in the first quarter worth about $44,000. Price T Rowe Associates Inc. MD lifted its holdings in Altimmune by 13.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,238 shares of the company’s stock worth $156,000 after purchasing an additional 1,821 shares during the last quarter. California State Teachers Retirement System lifted its holdings in Altimmune by 517.7% in the 1st quarter. California State Teachers Retirement System now owns 53,730 shares of the company’s stock worth $547,000 after purchasing an additional 45,032 shares during the last quarter. Tidal Investments LLC bought a new stake in Altimmune during the first quarter worth approximately $141,000. Finally, Cetera Advisors LLC grew its holdings in Altimmune by 19.6% during the first quarter. Cetera Advisors LLC now owns 60,800 shares of the company’s stock valued at $619,000 after purchasing an additional 9,977 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors.

Altimmune Stock Down 1.8 %

Altimmune stock opened at $8.57 on Monday. The business has a 50 day moving average price of $7.21 and a two-hundred day moving average price of $6.98. Altimmune, Inc. has a 12 month low of $3.16 and a 12 month high of $14.84. The stock has a market cap of $609.54 million, a price-to-earnings ratio of -5.53 and a beta of 0.09.

Altimmune (NASDAQ:ALT) last issued its earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million during the quarter. During the same quarter in the previous year, the company posted ($0.39) earnings per share. On average, analysts expect that Altimmune, Inc. will post -1.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ALT. B. Riley reaffirmed a “buy” rating and set a $20.00 price objective on shares of Altimmune in a report on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research report on Thursday, November 14th. UBS Group started coverage on Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company. Finally, Evercore ISI raised Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Altimmune has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.